TABLE 6.
KEGG enrichment analysis based on genes selected by RX.
| Pathways | Number of genes | P-value |
| Metabolic pathways (KEGG:01100) | 16 | 2.29E-05 |
| MAPK signaling pathway (KEGG:04010) | 9 | 7.79E-07 |
| Ras signaling pathway (KEGG:04014) | 7 | 3.23E-05 |
| T cell receptor signaling pathway (KEGG:04660) | 6 | 4.17E-06 |
| Parkinson’s disease (KEGG:05012) | 6 | 2.17E-05 |
| mTOR signaling pathway (KEGG:04150) | 6 | 3.36E-05 |
| Chemokine signaling pathway (KEGG:04062) | 6 | 9.50E-05 |
| PI3K-Akt signaling pathway (KEGG:04151) | 6 | 2.11E-03 |
| Pathways in cancer (KEGG:05200) | 6 | 4.32E-03 |
| Renal cell carcinoma (KEGG:05211) | 5 | 8.01E-06 |
| TGF-beta signaling pathway (KEGG:04350) | 5 | 2.26E-05 |
| Chagas disease (KEGG:05142) | 5 | 5.98E-05 |
| Osteoclast differentiation (KEGG:04380) | 5 | 1.76E-04 |
| Influenza A(KEGG:05164) | 5 | 6.32E-04 |
| Epithelial cell signaling in Helicobacter pylori infection (KEGG:05120) | 4 | 1.62E-04 |
| B cell receptor signaling pathway (KEGG:04662) | 4 | 2.10E-04 |
| Prostate cancer (KEGG:05215) | 4 | 4.32E-04 |
| Toll-like receptor signaling pathway (KEGG:04620) | 4 | 8.12E-04 |
| TNF signaling pathway (KEGG:04668) | 4 | 9.28E-04 |
| Apoptosis (KEGG:04210) | 4 | 2.19E-03 |